Javascript must be enabled to continue!
Diagnostic performance of Xpert MTB/RIF Ultra assay for tuberculosis in stool specimens among adult presumptive TB patients in a generalized HIV epidemic setting
View through CrossRef
Abstract
BACKGROUND
Diagnosis of Tuberculosis (TB) from stool specimen using the Xpert MTB/RIF Ultra assay (Xpert-Ultra assay) is important to confirm diagnosis for presumptive TB patients who are unable to produce sputum. We evaluated diagnostic performance of the Xpert-Ultra assay in stool specimen among adult migrant population living in generalized HIV epidemic situation.
METHODS
A prospective, cross-sectional study was conducted at outpatient and inpatient departments of the Shoklo Malaria Research Unit (SMRU) clinics and Mae Tao Clinic (MTC) located in Thailand-Myanmar border area. Presumptive TB patients of any age who were registered between November 14, 2022, and May 23, 2023, were eligible for inclusion based on reported signs and symptoms and/or radiological findings. Using liquid MTB culture in sputum as reference standard, evaluation of diagnostic performance of the Xpert-Ultra assay in stool was performed, and it was also compared with performance of smear microscopy and Xpert-Ultra assay in sputum specimen.
RESULTS
Total 113 participants were included in the analysis; 9 (7.96 %) had human immunodeficiency virus (HIV) infection, and 31 (27.43%) had confirmed TB on culture results. Among these culture-confirmed TB cases, the sensitivity of Xpert-Ultra assay in stool specimen was 90.32 % (95% confidence interval [CI], 74.25% to 97.96%). Although the absolute difference in sensitivity of Xpert-Ultra assay in stool was 3.23 % lower than sputum (95% CI: -9.46 % to 3.00 %), there was no statistically significant difference between the two sample types. The specificity of Xpert-Ultra assay in stool specimen was 98.78% (95% CI, 93.39% to 99.97%) against culture-negative TB cases, giving an absolute difference of 1.22 % (95% CI, -1.16% to 3.59%) compared to sputum Xpert-Ultra assay. This method demonstrated that diagnostic performance was consistent with World Health Organization (WHO) target product profiles on low-complexity assays for detecting
Mycobacterium tuberculosis
(MTB).
CONCLUSIONS
The Xpert-Ultra assay in stool specimen can be considered as a potential, alternative method in diagnosis of presumptive pulmonary TB in adults when respiratory sample is difficult to collect.
Title: Diagnostic performance of Xpert MTB/RIF Ultra assay for tuberculosis in stool specimens among adult presumptive TB patients in a generalized HIV epidemic setting
Description:
Abstract
BACKGROUND
Diagnosis of Tuberculosis (TB) from stool specimen using the Xpert MTB/RIF Ultra assay (Xpert-Ultra assay) is important to confirm diagnosis for presumptive TB patients who are unable to produce sputum.
We evaluated diagnostic performance of the Xpert-Ultra assay in stool specimen among adult migrant population living in generalized HIV epidemic situation.
METHODS
A prospective, cross-sectional study was conducted at outpatient and inpatient departments of the Shoklo Malaria Research Unit (SMRU) clinics and Mae Tao Clinic (MTC) located in Thailand-Myanmar border area.
Presumptive TB patients of any age who were registered between November 14, 2022, and May 23, 2023, were eligible for inclusion based on reported signs and symptoms and/or radiological findings.
Using liquid MTB culture in sputum as reference standard, evaluation of diagnostic performance of the Xpert-Ultra assay in stool was performed, and it was also compared with performance of smear microscopy and Xpert-Ultra assay in sputum specimen.
RESULTS
Total 113 participants were included in the analysis; 9 (7.
96 %) had human immunodeficiency virus (HIV) infection, and 31 (27.
43%) had confirmed TB on culture results.
Among these culture-confirmed TB cases, the sensitivity of Xpert-Ultra assay in stool specimen was 90.
32 % (95% confidence interval [CI], 74.
25% to 97.
96%).
Although the absolute difference in sensitivity of Xpert-Ultra assay in stool was 3.
23 % lower than sputum (95% CI: -9.
46 % to 3.
00 %), there was no statistically significant difference between the two sample types.
The specificity of Xpert-Ultra assay in stool specimen was 98.
78% (95% CI, 93.
39% to 99.
97%) against culture-negative TB cases, giving an absolute difference of 1.
22 % (95% CI, -1.
16% to 3.
59%) compared to sputum Xpert-Ultra assay.
This method demonstrated that diagnostic performance was consistent with World Health Organization (WHO) target product profiles on low-complexity assays for detecting
Mycobacterium tuberculosis
(MTB).
CONCLUSIONS
The Xpert-Ultra assay in stool specimen can be considered as a potential, alternative method in diagnosis of presumptive pulmonary TB in adults when respiratory sample is difficult to collect.
Related Results
Evaluasi sensitivitas dan spesifisitas Xpert MTB RIF dan Xpert MTB RIF Ultra pada berbagai spesimen untuk mendiagnosis tuberkulosis ekstra paru: Sebuah telaah literatur sistematis
Evaluasi sensitivitas dan spesifisitas Xpert MTB RIF dan Xpert MTB RIF Ultra pada berbagai spesimen untuk mendiagnosis tuberkulosis ekstra paru: Sebuah telaah literatur sistematis
Background: Molecular examination using Xpert MTB RIF and Xpert MTB RIF Ultra was introduced by WHO in 2010 as a fast and practical supporting examination in detecting Mycobacteriu...
Comparison of tests done, and Tuberculosis cases detected by Xpert® MTB/RIF and Xpert® MTB/RIF-Ultra in Uganda
Comparison of tests done, and Tuberculosis cases detected by Xpert® MTB/RIF and Xpert® MTB/RIF-Ultra in Uganda
Abstract
Background
Uganda introduced Xpert® MTB/RIF assay into its TB diagnostic algorithm in January 2012. In July 2018, this...
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
OSPHL in collaboration with APHL, will evaluate the performance of the Oxford Nanopore Technology sequencers for HIV genome sequencing using a modified protocol of the ARTIC amplic...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
The Value of Lateral Flow Urine Lipoarabinomannan Assay and Empirical Treatment in the Xpert MTB/RIF Ultra Era: a Prospective Cohort Study
The Value of Lateral Flow Urine Lipoarabinomannan Assay and Empirical Treatment in the Xpert MTB/RIF Ultra Era: a Prospective Cohort Study
Abstract
Introduction: The value of Lateral Flow urine Lipoarabinomannan (LF-LAM) assay and the role of empiric tuberculosis (TB) treatment in the era of the highly sensiti...
The value of lateral flow urine lipoarabinomannan assay and empirical treatment in Xpert MTB/RIF ultra negative patients with presumptive TB: a prospective cohort study
The value of lateral flow urine lipoarabinomannan assay and empirical treatment in Xpert MTB/RIF ultra negative patients with presumptive TB: a prospective cohort study
AbstractThe value of Lateral Flow urine Lipoarabinomannan (LF-LAM) assay and the role of empiric tuberculosis (TB) treatment in the era of the highly sensitive Xpert MTB/RIF Ultra ...
Comparison evaluation between gene Xpert Mtb/Rif and multiplex PCR for rapid diagnosis of mycobacterium tuberculosis
Comparison evaluation between gene Xpert Mtb/Rif and multiplex PCR for rapid diagnosis of mycobacterium tuberculosis
Abstract
Objective: To evaluate Gene Xpert MTB/RIF and Multiplex PCRfor detection of Mycobacterium tuberculosis and Rifampicin resistance comparing with gold standard MGIT 96...
Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia
Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia
Abstract
Background
The main advantage of GeneXpert MTB/RIF® (Xpert) molecular diagnostic technology is the rapid detection of M.tuberculosis DNA and mutations associated with rifa...

